Dr. Ellen G. Feigal is the Vice President, Research and Development at the California Institute for Regenerative Medicine (CIRM). Prior to joining CIRM in January, 2011, Dr. Feigal was Executive Medical Director, Global Development, at Amgen, where her primary focus was in clinical development of therapeutics in hematology/oncology. She also led the scientific/clinical interface with patient advocacy organizations, formalized the company's policy on expanded access to therapies for those with limited or no treatment options, and led the cross-functional teams to the company's first collaborative research and development agreement with the National Cancer Institute. From 2007 until joining CIRM, Dr. Feigal was adjunct professor and founding Director of the American Course on Drug Development and Regulatory Sciences, UC San Francisco, School of Pharmacy. The course, developed under her leadership as a collaborative effort with the FDA, UCSF's Department of Bioengineering and Therapeutic Sciences, its Center for Drug Development Sciences and the European Center of Pharmaceutical Medicine at the University of Basel, was launched in 2007.